Examples of using Opdivo in English and their translations into Vietnamese
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
There are no consequences for Opdivo in its authorised uses.
Opdivo(nivolumab) was approved for some people with small cell lung cancer.
What is happening with Opdivo for the treatment of other cancers?
OPDIVO will be given to you in hospital or clinic under the supervision of an experienced doctor.
For patients without HCC, withhold OPDIVO for Grade 2 and permanently discontinue OPDIVO for Grade 3 or 4.
Opdivo is used only if your tumor has a specific genetic marker that your doctor will test for.
The CHMP noted that in the main study Opdivo treatment led to a limited improvement in survival(around 1 month).
OPDIVO is a medicine that may treat your certain cancers by working with your immune system.
You will need frequent medical tests to help your doctordetermine if it is safe for you to keep receiving Opdivo.
In the absence of further data,it was not possible to establish that the benefits of Opdivo outweighed its risks for European patients.
The company informed the CHMP that the withdrawal does not have any consequences for patientscurrently included in clinical trials using Opdivo.
Therefore, at the time of the withdrawal,the CHMP was of the opinion that a benefit of Opdivo in the treatment of stomach cancer had not been demonstrated.
Treatment Opdivo and Yervoy for two months, starting in December 2014, then Opdivo alone for eight months, followed by lung surgery.
BMS will have nine drugs with more than $1 billion in annual sales,with an oncology pipeline including Opdivo, Revlimid, Pomylyst and Yervoy.
The active substance in Opdivo, nivolumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific structure.
The company's strong growth in 2018 can be in partattributed to continued success of leading drugs Opdivo(cancer) and Eliquis(a blood thinner).
Opdivo can cause your immune system to attack normal organs and tissues in many areas of your body, and can affect the way these organs work.
EvaluatePharma thinks that Eliquis will rank just behind Opdivo among the world's top-selling drugs in 2024, with total sales topping $10.5 billion.
However, Opdivo should still generate plenty of growth for BMS in the years to come, especially if it works well in combination with other therapies.
If approved, it would lessen some of Bristol-Myers' dependence on its immunotherapy Opdivo, which has faced stiff competition from Merck& Co's market leading rival drug Keytruda.
Opdivo's efficacy to treat squamous NSCLC was established in a randomized trial of 272 participants,of whom 135 received Opdivo and 137 received docetaxel.
Market research firm EvaluatePharma projects that Opdivo will be the No. 4 best-selling drug in the world by 2024 with sales of more than $11 billion.
OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma(see section 5.1).
Doctors at Memorial Sloan Kettering Cancer Center offered a 49-year old patient withmelanoma growths an experimental combination of two drugs: Opdivo and Yervoy, both of which are manufactured by Bristol-Myers Squibb.
For Hodgkin lymphoma, Opdivo is used if the condition has relapsed or progressed after stem cell transplant and treatment with brentixumab vedotin(Adcetris).
By the end of the year, the oncologists' toolbox contained two more medications that could be used after Nexavar in case of disease progression- the targeted treatment Stivarga(regorafenib)and the immunotherapy Opdivo(nivolumab).
OPDIVO(nivolumab) is indicated for the treatment of patients with metastatic small cell lung cancer(SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.
Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal,the CHMP had some concerns and was of the provisional opinion that Opdivo could not have been approved for the treatment of stomach cancer.
Opdivo(nivolumab), a type of immunotherapy, was approved to treat people with hepatocellular cancer, the most common type of liver cancer, who were previously treated with Nexavar(sorafenib), a type of targeted therapy.
But as the report only goes through 2017, the impact of many of the relatively new immunotherapies for lung cancer, such as Merck& Co's Keytruda,Bristol-Myers Squibb's Opdivo and others, as well as newer targeted treatments, have yet to be fully reflected in the mortality data.